{"id":1965,"date":"2020-03-17T10:14:00","date_gmt":"2020-03-17T09:14:00","guid":{"rendered":"https:\/\/www.corsiaffariregolatori.it\/it\/?p=1965"},"modified":"2022-01-17T10:15:58","modified_gmt":"2022-01-17T09:15:58","slug":"vaccines-post-marketing-vigilance","status":"publish","type":"post","link":"https:\/\/www.direnzo.biz\/it\/vaccines-post-marketing-vigilance\/","title":{"rendered":"The lifecycle of vaccines, from development to post-marketing vigilance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The word \u201c<strong>vaccine<\/strong>\u201d is now very much recurring in the daily news; it is important, then, to understand the steps that characterise the development of this particular type of&nbsp;<strong>medicines<\/strong>&nbsp;until they get into the market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We heard many times in these days, on the TV and social media, that for the development of a vaccine, the&nbsp;<strong>microorganism<\/strong>&nbsp;responsible for the&nbsp;<strong>disease<\/strong>&nbsp;must be well known. Starting from&nbsp;<em>in vitro<\/em>&nbsp;studies, the&nbsp;<strong>qualitative and quantitative composition<\/strong>&nbsp;of the vaccine can be defined and&nbsp;<strong>investigations<\/strong>&nbsp;can be started on animal models. Such investigations help to define the&nbsp;<strong>mechanism of action<\/strong>&nbsp;and the&nbsp;<strong>toxicological profile<\/strong>. The most effective&nbsp;<strong>formulations<\/strong>&nbsp;are thus selected to be investigated in humans.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, human clinical trials are far from being a final step: there can be up to three clinical trial phases in humans, with a progressive increase of the patients treated. Moreover, during these phases other factors are defined: the vaccine&nbsp;<strong>efficacy<\/strong>, any&nbsp;<strong>adverse reaction<\/strong>&nbsp;and whether a primary&nbsp;<strong>immunisation<\/strong>&nbsp;is sufficient or if a&nbsp;<strong>booster<\/strong>&nbsp;is necessary. The possibility of administering the vaccine together with other vaccines is also investigated.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Phase 3 clinical trials are particularly important because they confirm the&nbsp;<strong>efficacy<\/strong>&nbsp;and&nbsp;<strong>safety<\/strong>&nbsp;of the vaccine, and are in fact those involving the highest number of subjects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Once the trials are concluded, the relevant&nbsp;<strong>data<\/strong>&nbsp;are submitted to the competent&nbsp;<strong>authorities<\/strong>&nbsp;that will assess them from both a technical, scientific and&nbsp;<strong>regulatory<\/strong>&nbsp;point of view. Only in the case of a positive&nbsp;<strong>risk-benefit<\/strong>&nbsp;profile for humans, the vaccine assessment procedure will end with its&nbsp;<strong>approval<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For vaccines as well as for&nbsp;<strong>drugs<\/strong>, national or community procedures are in force: the competent authority would be therefore the&nbsp;<strong>European Medicine Agency<\/strong>&nbsp;(EMA) in case of a&nbsp;<strong>centralised procedure<\/strong>, or those of more Member States (in case of&nbsp;<strong>mutual recognition or decentralised procedures<\/strong>), or of a single State for&nbsp;<strong>national procedures<\/strong>. Only following the release of the relevant&nbsp;<strong>marketing authorisation<\/strong>, vaccines can be marketed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The vaccine process, however, does not end here. After its marketing,&nbsp;<strong>post-authorisation studies<\/strong>&nbsp;are started to control its efficacy and safety under real&nbsp;<strong>use conditions<\/strong>. Further information can also be obtained: this includes its&nbsp;<strong>cost-benefit profile<\/strong>&nbsp;compared to other products or its safety in use on&nbsp;<strong>special populations<\/strong>&nbsp;or in the presence of specific diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The results of these&nbsp;<strong>phase 4 trials<\/strong>&nbsp;could completely change the outcome of any previous assessment up to the marketing discontinuation of the vaccine. In fact, as reminded by the Italian Medicine Agency, vaccines are intended to be administered to healthy subjects for preventive purposes, and maximum efficacy and high superiority of its benefit against any&nbsp;<strong>possible risk<\/strong>&nbsp;are expected.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Finally, as vaccines have been a topic under discussion for many years, it is worth to remind some&nbsp;<strong>quality<\/strong>&nbsp;aspects, covering their&nbsp;<strong>development<\/strong>&nbsp;up to&nbsp;<strong>manufacturing<\/strong>&nbsp;and&nbsp;<strong>marketing<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">All vaccine development studies should comply with the&nbsp;<strong>Good Clinical Practice (GCP)<\/strong>&nbsp;standards, as provided for internationally, as its manufacturing process should meet the requirements of the&nbsp;<strong>Good Manufacturing Practice (GMP)<\/strong>, regularly controlled by specific&nbsp;<strong>inspections<\/strong>&nbsp;of the relevant authorities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The suitability of the manufacturing and the possible presence of contaminants developed during the manufacturing process are checked twice on each single batch before its delivery to&nbsp;<strong>vaccine centres<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Moreover, further controls are carried out by the manufacturer, by&nbsp;<strong>accredited laboratories<\/strong>&nbsp;and by other independent bodies during the whole manufacturing cycle of the vaccine and before its arrival on the market: this is the&nbsp;<strong>state control<\/strong>&nbsp;that is carried out on each batch in all European states.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The usual&nbsp;<strong>pharmacovigilance<\/strong>&nbsp;monitoring \u2013 applying to all&nbsp;<strong>medicinal products<\/strong>&nbsp;\u2013 adds to these controls as well as the annual&nbsp;<strong>random control<\/strong>&nbsp;of the composition by the&nbsp;<strong>High Health Institute (ISS)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vaccines are therefore safe and much controlled products, that can prevent the development and spreading of&nbsp;<strong>infective diseases<\/strong>, contributing to public health and increasing&nbsp;<strong>health safety<\/strong>&nbsp;standards.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SOURCE:&nbsp;<a href=\"http:\/\/www.agenziafarmaco.gov.it\/content\/vaccini\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/www.agenziafarmaco.gov.it\/content\/vaccini<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The word \u201cvaccine\u201d is now very much recurring in the daily news; it is important, then, to understand the steps that characterise the development of this particular type of&nbsp;medicines&nbsp;until they get into the market. We heard many times in these days, on the TV and social media, that for the development of a vaccine, the&nbsp;microorganism&nbsp;responsible<br \/><a class=\"moretag\" href=\"https:\/\/www.direnzo.biz\/it\/vaccines-post-marketing-vigilance\/\">+ Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":1966,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-1965","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts\/1965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/comments?post=1965"}],"version-history":[{"count":0,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts\/1965\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/media\/1966"}],"wp:attachment":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/media?parent=1965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/categories?post=1965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/tags?post=1965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}